Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ocular surface epithelial cells form the outermost layers of the cornea and conjunctiva, providing a physical and molecular barrier that shields the eye from mechanical injury, infection, and desiccation. These cells secrete and display transmembrane mucins, most notably MUC1, MUC4, and MUC16, which create a glycocalyx on the cell surface. The glycocalyx stabilizes the tear film, maintains hydration, reduces friction during blinking, and plays key roles in immune surveillance and protection against pathogens by modulating both physical barrier function and cell signaling. Dysregulation of epithelial cells or mucins can lead to ocular surface disorders such as dry eye disease, increased susceptibility to infection, or, less commonly, epithelial malignancies. Individual mucins (e.g., MUC16) have been targeted in disease models and are regarded as novel biomarkers for barrier function and epithelial health.
Stabilizing tear film by enhancing mucin secretion or function Modulating immune cell activity at the ocular surface Protecting and repairing epithelial barrier function
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ocular surface epithelial cells and mucins.